13F reference period
Q2 2026
Security Snapshot
SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) Institutional Ownership
CUSIP: 869367201
13F Institutional Holders and Ownership History from Q4 2025 to Q3 2026
Institutions Reporting
97
Shares (Excl. Options)
16.48M
Full value: 16,480,061 · shares · 30 Jun 2026Price
$33.20
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- STRO on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 16,480,061
- Total 13F value
- $545,669,309
- Portfolio coverage rank
- 0%
- Share change
- +2,358,449
- Value change
- +$88,214,262
- Number of holders
- 97
- Shares outstanding
- 16,987,643
- SEC-reported price per share
- $16.11
- Insider filing price
- $16.11
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- STRO - SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share is tracked under CUSIP 869367201.
- 97 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 69 to 97 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$351.11M
Full value: $351,112,986 · USD · 31 Mar 2026.$545.67M
Full value: $545,669,309 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 97 institutions filings for Q2 2026.
Security key
869367201
13F reference period
Q2 2026
13F holders
97
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
STRO full holder history
SUTRO BIOPHARMA, INC. SEC filings
SUTRO BIOPHARMA, INC. company facts
SUTRO BIOPHARMA, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 869367201:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
STRO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 7.9% | $39,967,433 | 1,304,846 | Perceptive Advisors LLC | 30 Jun 2026 | |||
| BIOTECHNOLOGY VALUE FUND L P | 7.6% | $13,306,506 | 1,251,788 | BVF PARTNERS L P/IL | 10 Feb 2026 | |||
| BlackRock, Inc. | 6.4% | $35,370,151 | 1,065,366 | BlackRock, Inc. | 30 Jun 2026 | |||
| Affinity Asset Advisors, LLC | 8.8% | $8,444,817 | 748,382 | Affinity Asset Advisors, LLC | 22 Jan 2026 | |||
| Point72 Asset Management, L.P. | 1.4% | $7,284,641 | 237,827 | Point72 Asset Management, L.P. | 30 Jun 2026 |
As of 30 Jun 2026,
97
institutional investors reported holding
shares of
SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO).
This represents
97%
of the company’s total
outstanding shares.
16.48M
Full value: 16,480,061 · shares · 30 Jun 202616.99M
Full value: 16,987,643 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
84%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 7.7% | 1,304,846 | +82% | 0.67% | $43,320,887 |
| BVF INC/IL | 7.4% | 1,251,788 | 0% | 1.1% | $41,559,362 |
| Affinity Asset Advisors, LLC | 6.9% | 1,172,487 | +9.6% | 1.9% | $38,926,568 |
| BlackRock, Inc. | 6.6% | 1,122,655 | +382% | 0% | $37,272,146 |
| SAMSARA BIOCAPITAL, LLC | 6.3% | 1,062,872 | 0% | 2.9% | $35,287,350 |
| Kynam Capital Management, LP | 5.1% | 872,558 | 0% | 1.6% | $28,968,926 |
| ORBIMED ADVISORS LLC | 4.4% | 743,944 | -7.1% | 0.47% | $24,698,941 |
| Balyasny Asset Management L.P. | 4.2% | 711,162 | +53% | 0.04% | $23,610,578 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.1% | 694,219 | -3.6% | 0% | $23,048,071 |
| EVENTIDE ASSET MANAGEMENT, LLC | 3.4% | 585,262 | -18% | 0.26% | $19,430,698 |
| Velan Capital Investment Management LP | 3% | 512,160 | 0% | 10% | $17,003,712 |
| Woodline Partners LP | 2.7% | 458,029 | +0.13% | 0.05% | $15,206,563 |
| ADAR1 Capital Management, LLC | 2.4% | 404,014 | -23% | 0.64% | $13,413,265 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 389,692 | +127% | 0% | $12,940,982 |
| ACADIAN ASSET MANAGEMENT LLC | 2.2% | 373,839 | +11% | 0.01% | $12,405,000 |
| MILLENNIUM MANAGEMENT LLC | 2.2% | 365,972 | +74% | 0.01% | $12,150,270 |
| STATE STREET CORP | 1.8% | 305,979 | +487% | 0% | $10,158,503 |
| Merck & Co., Inc. | 1.6% | 272,351 | 1.7% | $9,042,053 | |
| ACUTA CAPITAL PARTNERS, LLC | 1.6% | 270,251 | +0.31% | 6.3% | $8,972,333 |
| AMERIPRISE FINANCIAL INC | 1.4% | 244,669 | 0% | $8,123,011 | |
| Point72 Asset Management, L.P. | 1.4% | 237,827 | -66% | 0.01% | $7,895,856 |
| KVP Capital Advisors, LP | 1.3% | 226,575 | 0% | 5.5% | $7,522,290 |
| UBS Group AG | 1.2% | 208,512 | -47% | 0% | $6,922,599 |
| TWO SIGMA INVESTMENTS, LP | 1.2% | 201,688 | +209% | 0.01% | $6,696,042 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.2% | 197,562 | 0% | $6,559,058 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
4
Headline period
Q2 2026
Rows shown
1-4 of 4
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 173,421 | $2,793,859 | -$1,160,792 | $16.11 | 9 |
| 2026 Q2 | 16,480,061 | $545,669,309 | +$88,214,262 | $33.20 | 97 |
| 2026 Q1 | 14,095,307 | $351,112,986 | +$214,425,468 | $24.91 | 69 |
| 2025 Q4 | 5,308,429 | $61,441,352 | +$60,565,445 | $11.57 | 54 |